# The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

> **NCT03166098** · — · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 139 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder

## Interventions

- **DIAGNOSTIC_TEST:** Cognitive Function Assessments

## Key facts

- **NCT ID:** NCT03166098
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-05
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166098, "The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03166098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*